HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has announced promising results from the SAVANNAH Phase II trial, where the combination of TAGRISSO® and ORPATHYS® showed a significant response rate in patients with certain types of lung cancer resistant to existing treatments. This combination therapy targets MET-driven resistance, a common issue in patients with EGFR-mutated non-small cell lung cancer, and could represent a new treatment option for those who have exhausted other avenues.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
